Truist Financial Increases Edwards Lifesciences (NYSE:EW) Price Target to $95.00

Edwards Lifesciences (NYSE:EW) had its target price boosted by Truist Financial from $90.00 to $95.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “hold” rating on the medical research company’s stock. Truist Financial’s price objective would indicate a potential upside of 9.43% from the company’s previous close.

A number of other analysts have also recently commented on the stock. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a research note on Wednesday, April 1st. Citigroup boosted their price objective on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. TD Cowen reiterated a “buy” rating and issued a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Finally, Evercore restated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $98.95.

Edwards Lifesciences Stock Down 0.5%

EW stock traded down $0.45 during mid-day trading on Thursday, reaching $86.82. The company had a trading volume of 2,290,868 shares, compared to its average volume of 4,849,830. The company has a market capitalization of $49.99 billion, a price-to-earnings ratio of 46.24, a PEG ratio of 2.26 and a beta of 0.86. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29. The stock has a 50 day simple moving average of $87.12 and a two-hundred day simple moving average of $83.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the prior year, the business posted $0.64 EPS. The business’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total transaction of $56,762.30. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 45,577 shares of company stock worth $3,855,527 in the last ninety days. 0.31% of the stock is owned by company insiders.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of EW. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences during the 1st quarter worth $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences during the 4th quarter worth $27,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.